Clinical Performance of Apixaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Direct Electrical Current Cardioversion: A Prospective Propensity Score-Matched Cohort Study.

Anna RagoAndrea Antonio PapaAntonio CasseseGiulia ArenaMaria Cristina Giada MaglioccaAntonio D'OnofrioPaolo GolinoGerardo NigroVincenzo Russo

Published in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2019)

Newly initiated anticoagulation with apixaban in patients with nonvalvular AF scheduled for TEE-guided DCC seems to be as effective and safe as uninterrupted VKA therapy during 12 months of follow-up.

Keyphrases

atrial fibrillation
catheter ablation
direct oral anticoagulants
left atrial appendage
oral anticoagulants
venous thromboembolism
stem cells
cell therapy
smoking cessation